NCT07405151

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-03-27Est. Completion: 2027-06-12

Enrollment target: 60 participants

Locations

Masarykuv onkologicky ustav ( Site 4000), Brno, Brno-mesto, Czechia
Aichi Cancer Center ( Site 2702), Nagoya, Aichi-ken, Japan
Kanagawa Cancer Center ( Site 2701), Yokohama, Kanagawa, Japan
National Cancer Center Hospital ( Site 2700), Chūō, Tokyo, Japan
Oslo universitetssykehus, Radiumhospitalet ( Site 3501), Oslo, Norway
National Cancer Center ( Site 2902), Goyang-si, Kyonggi-do, South Korea
Asan Medical Center ( Site 2901), Seoul, South Korea
Samsung Medical Center ( Site 2900), Seoul, South Korea
Kantonsspital Graubünden-Medizin ( Site 3700), Chur, Kanton Graubünden, Switzerland
Hopitaux Universitaires de Geneve HUG ( Site 3701), Geneva, Switzerland
Chang Gung Memorial Hospital at Kaohsiung ( Site 3003), Kaohsiung City, Taiwan
China Medical University Hospital ( Site 3007), Taichung, Taiwan
National Cheng Kung University Hospital ( Site 3001), Tainan, Taiwan
National Taiwan University Hospital ( Site 3000), Taipei, Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 3010), Taipei, Taiwan

EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor

This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…

Seoul, South KoreaEst. completion Jun 2027

Esophageal Squamous Cell Carcinoma

This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation …

Multiple LocationsEst. completion Mar 15, 2032

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.